About

About bioAffinity Technologies Noninvasive early-stage lung cancer detection with high sensitivity, specificity and accuracy bioAffinity Technologies’ flagship product, CyPath® Lung, is a noninvasive test to improve the early detection of lung cancer in patients at high risk for the disease. CyPath® Lung uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin, meso-tetra (4-carboxyphenyl) porphyrin (TCPP), that is preferentially taken up by cancer and cancer-related cells. In a clinical study, CyPath® Lung demonstrated 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. CyPath® Lung can be used alone or in combination with other diagnostic tools. CyPath® Lung is marketed as a laboratory developed test by Precision Pathology Laboratory Services, a wholly owned subsidiary of bioAffinity Technologies.